The goal of the program is to produce outstanding biomedical scientists who expand the envelope of our knowledge of the mechanisms, manifestations, prevention, and cures of lung disease. The program combines intensive training in a single area of investigation within a multidisciplinary academic environment. The training is available at both the pre- and post-doctoral levels, supporting 4 pre-doctoral and 14 post-doctoral trainees per year. A PhD program may be completed in 5 years. At the postdoctoral level, qualified MD or PhD candidates complete 2 or more years of training. A wide range of training opportunities are provided by a large interactive network of faculty supported by individual, collaborative and inter-institutional research grants. These opportunities include lung-related research in behavioral science, cellular and molecular biology, environmental science, clinical trials, epidemiology, global health, immunology and infection, airway biology, sleep biology and vascular biology. The core of the experience is the close relationship between a primary mentor, co-mentors and the trainee. This is supplemented by individual development plans, formal course work, core conferences, training in responsible research conduct, communication skills, career planning, and grant writing. Postdoctoral trainees in the clinical sciences can acquire a Masters or Doctoral degree. Fellows and mentors are reviewed by a committee that monitors the training and career development of fellows, and promotes mentoring skills. Doctoral students are reviewed by a thesis committee that provides both support and guidance. Over 15 years, 85% of graduates take 3 or more years of training supported by 56 individual F32 NRSA awards, and 95% of graduates take full-time academic positions after graduation. Our graduates have been awarded 47 mentored K awards, and 19 other non-government career development awards. Thus, the program has met its goal to train the next generation of leaders in lung research.

Public Health Relevance

Lung disease is a leading cause of death and disability in the United States. Despite an expanding understanding of the causes of lung disease, treatments that cure these disorders are lacking and most treatments are symptomatic or supportive. The goal of this program is to train highly qualified individuals in the research disciplines that are necessary to find better treatments for these disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007534-38
Application #
9975208
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Kalantari, Roya
Project Start
1982-07-01
Project End
2023-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
38
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Turnbull, Alison E; Sahetya, Sarina K; Colantuoni, Elizabeth et al. (2018) Inter-Rater Agreement of Intensivists Evaluating the Goal Concordance of Preference-Sensitive ICU Interventions. J Pain Symptom Manage 56:406-413.e3
Mallow, Christopher; Thiboutot, Jeffrey; Semaan, Roy et al. (2018) External beam radiation therapy combined with airway stenting leads to better survival in patients with malignant airway obstruction. Respirology :
Qu, Yanyan; Olonisakin, Tolani; Bain, William et al. (2018) Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis. JCI Insight 3:
Mallow, Christopher; Hayes, Margaret; Semaan, Roy et al. (2018) Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med 12:605-614
Hager, David N; Tanykonda, Varshitha; Noorain, Zeba et al. (2018) Hospital mortality prediction for intermediate care patients: Assessing the generalizability of the Intermediate Care Unit Severity Score (IMCUSS). J Crit Care 46:94-98
Law, Anica C; Sahetya, Sarina; Walkey, Allan J et al. (2018) Low-dose corticosteroids and septic shock resolution: implications for randomized trial design? Intensive Care Med 44:1366-1367
Mills, Kelly A; Greene, M Claire; Dezube, Rebecca et al. (2018) Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis. Int J Geriatr Psychiatry 33:642-651
Suresh, Karthik; Servinsky, Laura; Jiang, Haiyang et al. (2018) Reactive oxygen species induced Ca2+ influx via TRPV4 and microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 314:L893-L907
Raju, Sarath; Keet, Corinne A; Paulin, Laura M et al. (2018) Rural Residence and Poverty are Independent Risk Factors for COPD in the United States. Am J Respir Crit Care Med :
Mallow, Christopher; Isakow, Warren (2018) Risk Factors for Loss of Lung Sliding in a Medical Intensive Care Population With Acute Respiratory Failure. J Bronchology Interv Pulmonol :

Showing the most recent 10 out of 112 publications